

Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
The protocol for the use of dronedarone 400mg tablets (multaq®) in the maintenance of sinus rhythm for adult patients with paroxysmal or persistent atrial fibrillation. The document details the initiation and maintenance responsibilities of consultants and gps, as well as important drug interactions and patient monitoring requirements. It also includes advice for patients regarding grapefruit juice and st. John's wort.
Typology: Study Guides, Projects, Research
1 / 2
This page cannot be seen from the preview
Don't miss anything!
Lead reviewer: Cardiovascular review group Approved by: Formulary Subgroup of NHS Highland ADTC Date: March 2012 Review date: March 2013 Version: 1 Warning documents uncontrolled when printed
Drug
Dronedarone 400mg tablets (Multaq ®)
Indication
Maintenance of sinus rhythm in adult clinically stable patients with paroxysmal atrial fibrillation or persistent atrial fibrillation after cardioversion. Treatment will be initiated in patients without heart failure after other drugs have been considered.
Dosage
400mg twice daily, with morning and evening meals.
Initiation and maintenance of treatment – delineation of responsibilities
Initiation - Treatment will be initiated by a consultant cardiologist
Before treatment is started, the consultant will record an ECG and serum creatinine, potassium and magnesium, and LFTs.
Treatment with Class I or III antiarrhythmics (such as flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol, amiodarone) will be stopped before starting dronedarone.
The consultant is responsible for ensuring that there are no contra-indications or clinically significant drug interactions when treatment with dronedarone is started.
The consultant will inform the patient of the monitoring that the GP will carry out and of any symptoms that should be reported to the GP (see below).
Continuation of treatment - GP’s responsibilities
Measure LFTs
If alanine transaminase (ALT) levels are elevated to ≥ 3 times upper limit of normal (ULN), retest within 48 to72 hours. If ALT levels are confirmed to be ≥ 3 times ULN after retesting, withdraw dronedarone treatment.
As previously advised by the consultant, the GP will advise patients to report any of the following symptoms immediately:
Note that dronedarone is a newly licensed medicine under intense monitoring by the MHRA. All suspected adverse reactions to dronedarone should be reported to the MHRA via the Yellow Card Scheme at www.yellowcard.gov.uk.
Lead reviewer: Cardiovascular review group Approved by: Formulary Subgroup of NHS Highland ADTC Date: March 2012 Review date: March 2013 Version: 1 Warning documents uncontrolled when printed
Drug interactions
Dronedarone has many important potential drug interactions. These will be considered when treatment is initiated. No medicine should be added to or withdrawn without consulting with Appendix 1 of the BNF, the Summary of Product Characteristics and, if necessary, the cardiologist.
Of particular note are interactions with:
Advice to patients
References
Summary of Product Characteristics, available at http://www.medicines.org.uk/EMC/medicine/22894/SPC/Multaq+400mg+tablets/
British National Formulary 61 (March 2011)
‘Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements’ MHRA Update, October 2011, available at http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con131944.pdf